These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 12160194)

  • 1. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
    Weinberger MH; Roniker B; Krause SL; Weiss RJ
    Am J Hypertens; 2002 Aug; 15(8):709-16. PubMed ID: 12160194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
    Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
    J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
    Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
    Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.
    Pelliccia F; Patti G; Rosano G; Greco C; Gaudio C
    Int J Cardiol; 2014 Nov; 177(1):219-28. PubMed ID: 25499383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
    Li JS; Flynn JT; Portman R; Davis I; Ogawa M; Shi H; Pressler ML
    J Pediatr; 2010 Aug; 157(2):282-7. PubMed ID: 20400095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
    Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
    Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
    Tomaschitz A; Verheyen N; Meinitzer A; Pieske B; Belyavskiy E; Brussee H; Haas J; März W; Pieske-Kraigher E; Verheyen S; Ofner-Ziegenfuss L; Hartaigh BÓ; Schwetz V; Aberer F; Grübler M; Lang F; Alesutan I; Voelkl J; Gaksch M; Horina JH; Dimai HP; Rus-Machan J; Stiegler C; Ritz E; Fahrleitner-Pammer A; Pilz S
    J Hypertens; 2016 Jul; 34(7):1347-56. PubMed ID: 27065001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.
    Parthasarathy HK; Ménard J; White WB; Young WF; Williams GH; Williams B; Ruilope LM; McInnes GT; Connell JM; MacDonald TM
    J Hypertens; 2011 May; 29(5):980-90. PubMed ID: 21451421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone for hypertension.
    Tam TS; Wu MH; Masson SC; Tsang MP; Stabler SN; Kinkade A; Tung A; Tejani AM
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008996. PubMed ID: 28245343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
    Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Saruta T; Kageyama S; Ogihara T; Hiwada K; Ogawa M; Tawara K; Gatlin M; Garthwaite S; Bittman R; Patrick J
    J Clin Hypertens (Greenwich); 2004 Apr; 6(4):175-83; quiz 184-5. PubMed ID: 15073471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of aldosterone blockade.
    Weber MA
    Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.